In conclusion, we have generated TMZ-resistant GBM cell lines whose resistance cannot be explained by high MGMT activities or MMR deficiency, the currently two known determinants of clinical response to TMZ in patients with GBM. This evidence concerns the gene MGMT and glioblastoma.